A new randomized trial
HOTFy reported improvements during HBOT, with some benefits declining after treatment ended. Its delayed-treatment design is an important part of interpreting the results.
Read the fibromyalgia researchRX-O2 • Scottsdale & Glendale, Arizona
Explore the science behind hyperbaric oxygen therapy, from established medical uses to conditions still being studied. Find the evidence, understand its limits, and discuss what it means for your care.

The research conversation
New publications add to the evidence. The study design and the results both matter.
HOTFy reported improvements during HBOT, with some benefits declining after treatment ended. Its delayed-treatment design is an important part of interpreting the results.
Read the fibromyalgia researchThe PARADOX pilot adds clinical and imaging observations from 16 patients. It supports further investigation, with a controlled trial needed to confirm benefit.
Read the ulcerative colitis researchTwo trials found no significant benefit from shorter HBOT courses over comparison treatments. Those findings belong alongside earlier positive studies.
Read the long covid researchThe evidence library
Browse 41 topics and 114 selected publications. Open a topic to read the evidence summary and original sources.
Literature check
How to read the labels: “Specialist clinical use” describes an established or selected clinical role, not a guarantee of strong trial evidence. “Under study” includes emerging, mixed, or unsupported uses. “Background science” explains mechanisms. These labels do not indicate FDA approval or insurance coverage.
The clinical studies below concern people receiving methadone. Animal withdrawal findings cannot establish relapse prevention or replace medications and behavioral care.
Reduced some physical withdrawal behaviors, without changing the motivated behaviors tested. These findings are not clinical relapse-prevention evidence.
Found promising symptom trends in adults receiving methadone; designed to support a larger study, not establish efficacy.
Explored supervised methadone dose reduction. Small enrollment and incomplete treatment participation limit conclusions.
Cognitive scores, brain imaging, and animal findings answer different questions. HBOT has not been established as a cure or a way to reverse Alzheimer’s disease.
Examined amyloid, mitochondrial recycling, and inflammation in mice. These results do not demonstrate effectiveness in people.
Pooled cognitive outcomes favored HBOT; the authors called for more rigorous studies to define its clinical value.
Reported short-term cognitive changes in Alzheimer’s disease and mild cognitive impairment; does not establish altered disease progression.
Adult recovery after cardiac arrest and newborn hypoxic injury are different clinical settings. These findings do not establish routine HBOT for near-drowning recovery or all forms of brain injury.
Reviews experimental approaches to perinatal hypoxic injury; these findings cannot be generalized to routine pediatric recovery.
Reported cognitive changes in 11 people after cardiac arrest. A small uncontrolled series cannot prove efficacy.
A trial after knee replacement addresses postoperative recovery, not reversal of osteoarthritis. Mouse studies of immune signaling do not establish clinical benefit in rheumatoid arthritis.
Examined cartilage and circulation in experimental osteoarthritis. It does not establish cartilage repair in patients.
Studied early recovery after knee replacement, including muscle injury and inflammation. It did not test reversal of arthritis.
Examined immune-cell responses in experimental arthritis. Clinical effectiveness in rheumatoid arthritis remains unproven.
The studies used different pressures, oxygen concentrations, and outcomes. HBOT is not an established treatment for autism; developmental and behavioral supports remain central to care.
Reported improvements across some outcomes, but poor study quality and substantial differences between studies limit confidence.
Found no evidence of benefit in the eligible controlled trial and identified ear barotrauma as a possible adverse effect.
Both groups improved; HBOT did not provide an overall clinically meaningful advantage over sham exposure.
Reported some improvements using 1.3 ATA and 24% oxygen. This exposure differs from medical HBOT with 100% oxygen.
An erratum is indexed for this article. Consult the publisher’s corrected record.
Stage, joint collapse, and orthopedic treatment matter. A 2025 meta-analysis did not establish superiority over comparison treatments, despite improvements within some treated groups.
Reported reduced lesion size after treatment. Imaging change alone does not establish protection from future joint collapse.
Within-group improvements did not translate into clear superiority over comparison treatments; the authors called for stronger trials.
Reported early pain and movement benefits. After crossover, the long-term follow-up became observational.
This is a hospital indication. HBOT must fit within urgent infection management and must not postpone drainage, antibiotics, or neurosurgical care.
Reported clinical and imaging outcome differences in brain abscess care. Nonrandomized comparisons leave uncertainty about causation.
Discusses adjunctive HBOT in selected intracranial infections alongside definitive treatment.
Reported fewer treatment failures and better outcomes with adjunctive HBOT; prospective confirmation is needed.
Burn severity, timing, and access to critical care affect suitability. The published evidence does not support a guaranteed reduction in operations, hospital stay, or mortality.
Found possible healing benefits but substantial variation and inconsistent mortality findings; stronger trials are needed.
Discusses adjunctive HBOT in thermal injury, with careful selection and critical-care monitoring.
HBOT is not a substitute for oncology treatment. Care for a person with cancer requires coordination with the oncology team, including review of current medicines and the reason for HBOT.
Investigated a liposomal chemotherapy combination. This is not evidence to recommend that combination clinically.
Investigated HBOT combined with a ketogenic diet in mice. HBOT alone did not change cancer progression in this model.
Reviews tumor-growth and safety questions. It does not establish HBOT as a stand-alone cancer treatment.
For treatment-related tissue damage, see radiation tissue injury research.
Suspected poisoning requires emergency assessment and oxygen treatment. Selection for HBOT is an urgent medical decision, not an outpatient consultation booking.
Examines treatment pressure and later neurological outcomes. This is not a protocol recommendation for unsupervised use.
Explains neurological and cardiac injury, emergency care, and the role of oxygen-based treatment.
Reported fewer delayed cognitive problems after acute carbon monoxide poisoning with the regimen studied.
Some research combines HBOT with other interventions, making its independent contribution uncertain. Heart conditions also affect the safety assessment before treatment.
Examines HBOT together with counterpulsation and standard medicines, so HBOT’s independent contribution is uncertain.
Summarizes cardiac injury and inflammatory markers; limited, heterogeneous studies do not establish routine clinical benefit.
Different comparison treatments and study sizes limit certainty. HBOT is not established as routine cerebral palsy care and should not replace individualized rehabilitation.
Reported gait and balance improvements with HBOT plus physical therapy. The comparison group received physical therapy without sham exposure.
Found similar functional improvement in HBOT and pressurized-air groups; ear problems were more common with HBOT.
Pain has many causes. Results in CRPS cannot be assumed to apply to all neuropathic pain, back pain, or chronic pain syndromes.
Summarizes potential CRPS benefits while identifying a need to refine patient selection and treatment protocols.
Reported pain and function changes after HBOT. Without a randomized comparator, the treatment effect remains uncertain.
Found improvements in pain, swelling, and several wrist movement measures. Wider confirmation and longer follow-up are needed.
Urgent surgical assessment comes first, particularly when a correctable blood-flow problem is suspected. Findings in compromised tissue do not imply a benefit for every healthy graft.
Suggests potential benefit after ischemic breast reconstruction complications; studies were mostly small and observational, with low certainty.
Reported improved graft outcomes in diabetic foot reconstruction. Randomized confirmation is needed.
Explains salvage of compromised tissues. Human evidence was largely case reports and series.
Two HOT-TOPIC publications follow the same 20-patient cohort. A newer small Mayo Clinic series highlights the gap between symptom relief and sustained fistula healing.
Some patients reported symptom relief, but objective improvement was limited and most had progression requiring further surgery.
Reported maintained improvements at one year in the HOT-TOPIC cohort. This follows the same patients as the 2021 publication.
Reported clinical and imaging changes in 20 patients with refractory perianal fistulas; it was not a randomized sham-controlled trial.
These are time-sensitive emergencies requiring an appropriate emergency hyperbaric service. A research listing does not imply that RX-O2 provides every emergency service described here.
Describes emergency HBOT after a lung-biopsy gas embolism. A case illustrates management but cannot estimate treatment success rates.
Examines altitude-related decompression illness and treatment experience. This is an emergency-service context.
Explains gas embolism and the rationale for urgent hyperbaric treatment.
Patient selection matters. Blood flow, infection control, pressure offloading, debridement, and diabetes management remain essential; HBOT is not a treatment for diabetes itself.
Reported a favorable association, but adjustment for additional confounders reduced statistical certainty.
Conditionally supports selected adjunctive wound treatments when good standard care is insufficient; certainty remains limited.
HODFU found improved healing in selected chronic diabetic foot ulcers. It supports careful selection within comprehensive wound care.
Uncontrolled improvements cannot isolate a treatment effect. Fatigue also warrants evaluation for other causes, and the demands of frequent clinic visits matter for people with ME/CFS.
Reported improvements in ME/CFS symptoms and function alongside imaging changes. A controlled trial is needed to establish causation.
Reported improvements in fatigue scores in 16 patients. The authors called for larger studies with control groups.
An erratum is indexed for this article. Consult the publisher’s corrected record.
The 2026 HOTFy trial adds to this literature but used a delayed-treatment comparison, not sham exposure. Some benefits diminished after treatment stopped.
Found pain benefits in a small body of trials in women; quality-of-life and long-term effects remained uncertain.
HOTFy found improvements during treatment. Some outcomes moved back toward standard-care levels after HBOT stopped; there was no sham group.
Compared HBOT with medication in fibromyalgia following TBI. This selected population limits generalization to all fibromyalgia.
Reported improvements against a no-treatment observation period. The design did not control for all effects of the chamber experience.
The selected reviews cover mechanisms, clinical indications, and adverse effects. Safe delivery requires appropriate equipment, trained staff, patient screening, and ongoing monitoring.
Reviews adverse effects and the importance of weighing benefit against risk for the individual patient.
A framework for accepted and non-accepted indications; recommendations differ in strength and certainty. Read with the published correction.
Explains oxygen-dependent signaling and why clinical evidence must be assessed separately for each indication.
FDA guidance on safe use of HBOT devices addresses equipment instructions, training, monitoring, and fire prevention.
The cause of bladder symptoms matters. Findings in one form of cystitis do not establish benefit for every urinary condition.
Links symptom changes with tissue markers after treatment; this does not prove that the proposed pathway causes clinical benefit.
Reported sustained symptom improvement in some treatment-resistant patients. There was no randomized comparison group.
Reported benefit in a subset of patients with interstitial cystitis. The small study leaves substantial uncertainty.
An erratum is indexed for this article. Consult the publisher’s corrected record.
For treatment-related tissue damage, see radiation tissue injury research.
Different protocols and patient groups may contribute to differing results. A positive pilot study does not resolve the uncertainty shown in sham-controlled trials.
Reported symptom improvements among participants completing treatment. Controlled studies are needed to separate treatment effects from other influences.
Found no significant differences in symptoms, function, or cognition between the four oxygen and pressure regimens studied.
HOT-LoCO found no significant advantage for 10 HBOT sessions on its primary physical-function outcomes at 13 weeks.
Reported cognitive and symptom benefits after 40 sessions. Short follow-up and a selected patient group limit broad conclusions.
A case report cannot establish effectiveness, bacterial eradication, or a standard protocol. HBOT is an off-label consideration and does not replace guideline-based Lyme evaluation and treatment.
Reports one patient’s experience. It cannot establish effectiveness for Lyme disease or persistent post-treatment symptoms.
IDSA/AAN/ACR Lyme disease guideline provides the clinical context for diagnosis and standard treatment.
A result in post-stroke depression cannot be generalized to every depressive disorder. HBOT should not replace established psychiatric care or prescribed medication.
Reported short-term improvements in post-stroke depression and inflammatory markers. Long-term effectiveness remains uncertain.
Suggests potential symptom benefits, but studies were generally small and results varied across diagnoses and comparison treatments.
Oxygen at normal atmospheric pressure for cluster headache is a different treatment from HBOT. Evidence for one should not be presented as evidence for the other.
Found limited evidence for acute migraine relief with HBOT. Normal-pressure oxygen evidence for cluster headache is a separate question.
Reported reduced subjective migraine pain; its small scope does not establish a preventive treatment strategy.
This topic is included to make the research transparent. A biological mechanism or favorable individual experience is not sufficient evidence of improved disease course.
Examined immune effects in experimental autoimmune encephalomyelitis. It does not establish a treatment effect in people with MS.
Found no clinically meaningful overall benefit and did not recommend routine HBOT for multiple sclerosis.
Did not change overall disease progression or relapse rate; most outcomes did not differ between groups.
Emergency surgery, source control, and antibiotics are essential. Transfer for HBOT must not delay these treatments; most outcome comparisons are not randomized.
Found an association with lower mortality in Fournier’s gangrene; nonrandomized studies cannot eliminate selection bias.
Discusses adjunctive HBOT within aggressive multidisciplinary infection care; urgent surgery and antibiotics remain essential.
The surgical team should assess unexpected pain, skin changes, or wound breakdown promptly. Published recovery and salvage rates are not guarantees for an individual procedure.
Reports encouraging clinical series, but the pooled complication estimate was not statistically significant and studies were highly heterogeneous.
Describes healing after breast reconstruction. The authors explicitly note that the absence of a control group prevents causal conclusions.
Discusses HBOT in complex secondary rhinoplasty, particularly compromised tissue. It does not establish routine benefit after uncomplicated surgery.
Veteran studies often include overlapping TBI and PTSD symptoms. A small preliminary dose-comparison study cannot establish effectiveness against placebo.
Reports the first nine completed cases. Both groups received HBOT, and the difference between doses was not statistically significant.
Reported sustained symptom improvements in veterans. The authors call for controlled trials to confirm efficacy.
Reported improvements in postconcussion and PTSD symptoms at 13 weeks, but the changes did not persist beyond six months.
Results differ between bladder, bowel, breast, jaw, and other tissues. The reason for treatment, prior procedures, and current symptoms guide the clinical assessment.
RICH-ART reported sustained urinary symptom improvement over five years. After crossover, the long-term analysis lacked an untreated comparison group.
Offering HBOT reduced fibrosis but did not significantly reduce pain in the main analysis; findings differed among treatment completers.
Supports possible benefits for selected late radiation injuries, with uncertainty by tissue and severity and recognized adverse effects.
The evidence is largely observational and differs by infection site. A recent review of sternal infections could not establish an added HBOT effect beyond the rest of the care pathway.
Found sparse, heterogeneous evidence for sternal infections and could not isolate an added HBOT effect beyond multimodal treatment.
Discusses adjunctive use in refractory disease and the need to reassess surgery and antibiotics if infection persists.
Summarizes mostly cohort reports and case studies of HBOT added to antibiotics and debridement for chronic osteomyelitis.
Acute respiratory illness and long COVID are different conditions. Laboratory markers alone do not demonstrate improved survival or support using HBOT instead of emergency respiratory care.
Examines blood-metabolite changes. These are exploratory biological findings rather than proof of improved survival or routine benefit.
Studies critically ill COVID patients and biological responses. Its hospital setting and small scale limit generalization.
Sudden vision loss is an emergency. An eye and stroke assessment must not be delayed while arranging HBOT; findings do not apply to all eye disorders.
Suggests better outcomes with early treatment; timing, study design, and baseline differences limit certainty.
Summarizes HBOT and thrombolysis studies. It does not establish superiority through a definitive head-to-head trial.
Examines visual recovery and retinal findings after HBOT. The design cannot establish the benefit for every patient with CRAO.
This is a hospital-level indication requiring treatment of the cause of anemia and close monitoring. It is different from routine management of iron deficiency or fatigue.
Reviews temporary oxygen support for exceptional severe anemia in acute hospital care.
Describes HBOT alongside vitamin B12 treatment when transfusion could not be used. It does not establish routine anemia treatment.
Human clinical results and animal healing experiments are different levels of evidence. The studies do not support a universal percentage improvement or return-to-play promise.
Found more consistent findings in some bone conditions; evidence for ligament, tendon, and muscle recovery remained inconclusive.
Found benefits in some muscle-injury measures but not overall exercise-related soreness; outcomes and protocols varied.
Found no benefit for the measured markers of exercise-induced muscle injury or soreness.
Results depend on the population and measurement. A study in irradiated patients found much smaller cell-mobilization effects, illustrating why a single percentage should not be promised to everyone.
Reported changes in isolated blood-cell telomeres and senescence markers. It did not demonstrate longer life or reversal of whole-body aging.
Found only minor stem-cell mobilization in irradiated patients, illustrating that effects differ by patient group and measurement.
Examines circulating stem/progenitor cells and nitric-oxide signaling. Cell counts are not the same as a demonstrated clinical outcome.
Research in chronic recovery is separate from acute stroke treatment. Suspected stroke requires emergency care, and HBOT must never postpone time-sensitive stroke treatment.
Reported benefits from HBOT plus computerized cognitive training. The findings concern a combined rehabilitation approach.
Both groups improved; between-group motor and cognitive comparisons were not statistically significant.
Reported improvements in chronic stroke recovery compared with a no-treatment period; it did not test acute stroke care.
Sudden hearing loss needs urgent ENT assessment. This evidence concerns acute sensorineural loss, not routine age-related hearing loss or tinnitus alone.
Found moderate evidence of hearing benefit when HBOT was added to steroid treatment; optimal dose and timing need further study.
Pooled randomized trials favored HBOT as part of combination treatment. The available trial population was small.
Describes HBOT with steroids as an option for selected sudden sensorineural hearing loss, with attention to early treatment.
Mild chronic symptoms and acute severe brain injury are different clinical questions. Results depend on the population, comparison treatment, and outcome being measured.
Found benefits in some cognitive and sleep outcomes, but not several other measures; applicability to more severe TBI was limited.
Found no advantage over sham chamber exposure for persistent postconcussion symptoms in service members.
Reported cognitive and quality-of-life gains against an observation period. No sham exposure was used.
Trauma surgery, restoration of blood flow, and treatment of compartment syndrome take priority. HBOT supports a coordinated trauma pathway rather than replacing urgent treatment.
Reports outcomes after earthquake-related crush injuries. Injury severity and selection limit conclusions about HBOT’s independent effect.
HOLLT found less tissue necrosis and fewer late complications, but its primary composite outcome was not statistically significant.
A published trial protocol describes planned research, not results. Severe flares require gastroenterology-led care; current evidence does not establish HBOT as a replacement for standard treatment.
PARADOX enrolled 16 people with refractory UC and reported responses in some patients. A controlled trial is needed to confirm the findings.
Describes a planned multicenter sham-controlled study in hospitalized UC flares. Publication of the protocol is not evidence of benefit.
All participants initially received HBOT plus steroids; responders were randomized to different treatment durations. It was not an HBOT-versus-sham efficacy trial.
Found no significant added benefit over conventional treatment during a severe UC attack.
Try a broader term or use “Clear filters” above.
PubMed links open a live search sorted by publication date. Those results can include papers not yet assessed in this library. Research listings do not mean every condition is suitable for treatment or every hospital service is available at RX-O2.
Read beyond the headline
A long list of papers is only a starting point. The question is what those papers can tell us about care for a particular person.
Explore mechanisms and safetyThis is a selected educational library, not an exhaustive systematic review. Summaries reflect the cited publications and their limitations. The literature-check date records this reference update; it does not indicate an independent physician review of every paper.
Scottsdale & Glendale
Our physician-led team reviews your history, goals, and suitability for hyperbaric care. RX-O2’s medical director is Marvin A. Borsand, DO, FACOS, FACCS.
HBOT requires medical evaluation and a prescription. FDA clearance of a chamber does not mean every condition listed here is an FDA-cleared indication. Outcomes vary, and risks include ear pressure injury, temporary vision changes, and oxygen-related adverse effects. Electronics and battery-powered devices are not permitted inside RX-O2 chambers.
For suspected stroke, poisoning, severe infection, or sudden vision loss, seek emergency care; do not wait for an outpatient appointment. Sudden hearing loss needs urgent medical assessment.